Diabetic patients with chronic kidney disease may benefit more from GLP-1 analogue treatment
Prof. Neil Poulter gives an overview of a subgroup analysis of the LEADER trial in which patients with CKD treated with liraglutide showed a reduction of CV events as compared with those on placebo treatment.
Video navigation menu
- The overall trial design of LEADER 01:35
- Focusing on CKD subgroups - CV outcomes 03:32
- In search of an explanation for the greater treatment effect in those with lower eGFR or proteinuria 07:40
- Safety findings with liraglutide in these subgroups 08:34
- Conclusions 09:17
Persons with type 2 diabetes are at an elevated risk for cardiovascular disease. LEADER study data have shown that treatment with the GLP-1 agonist liraglutide gives cardiovascular benefits to patients with T2DM. This recording aims to summarise findings of the LEADER trial in a subgroup of patients with chronic kidney disease.
Prof. Neil Poulter, FMedSci, cardiologist, Faculty of Medicine, National Heart & Lung Institute; Professor of Preventive Cardiovascular Medicine, Imperial College London, United Kingdom, Member of the Executive Board and President Elect of the International Society of Hypertension
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.